GlassScriptPhysician profile
Stuart A Krauss
NPI 1336166875
$16,998.49
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,104 · 2020: $3,058 · 2021: $1,427 · 2022: $4,777 · 2023: $2,564 · 2024: $69.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.16 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,212.57 | 2020-2023 | Zejula, Jemperli, Ojjaara |
| Janssen Biotech, INC. | $1,954.39 | 2019-2023 | Rybrevant |
| Exelixis INC. | $1,470.00 | 2022 | |
| R-Pharm US LLC | $1,367.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,270.21 | 2019-2024 | Kisqali, Piqray |
| E.R. Squibb & Sons, L.L.C. | $1,196.89 | 2019-2023 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,004.57 | 2019-2023 | Lynparza, Tagrisso |
| Genentech USA, INC. | $814.08 | 2019-2023 | Tecentriq, Venclexta, Alecensa |
| Pfizer INC. | $756.07 | 2019-2023 | |
| Seagen INC. | $643.99 | 2019-2023 | Adcetris, Padcev |
| Merck Sharp & Dohme LLC | $474.59 | 2019-2023 | Keytruda |
| Daiichi Sankyo INC. | $373.93 | 2022-2023 | Enhertu |
| Celgene Corporation | $321.81 | 2019-2023 | Pomalyst |
| Adc Therapeutics America, INC. | $307.13 | 2021-2022 | |
| Amgen INC. | $303.56 | 2019-2023 | Lumakras, Vectibix, Nplate |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Krauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.